Drug Trial Radar · NCT07777861
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Oct 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma, providing supportive evidence for the design of subsequent clinical trials. The secondary objectives are to evaluate the safety, pharmacokinetic profiles, and immunogenicity of G01 Eye Drops in the target patient population.
Conditions
- Primary Open-Angle Glaucoma
- Optic Nerve Injury
Interventions
G01 Eye Drops 100μg/mlDrug
Investigational G01 Eye Drops (100 μg/mL), administered topically to the eye, twice daily, one drop (approximately 33 μL) per dose, for a 24-week treatment period, for patients with optic nerve injury associated with primary open-angle glaucoma.
G01 Eye Drops 200μg/mlDrug
Investigational G01 Eye Drops (200 μg/mL), administered topically to the eye, twice daily, one drop (approximately 33 μL) per dose, for a 24-week treatment period, for patients with optic nerve injury associated with primary open-angle glaucoma.
Placebo of G01 Eye DropsDrug
Matched placebo eye drops, identical in appearance, viscosity and packaging to G01 Eye Drops. Administered topically to the eye, twice daily, one drop (approximately 33 μL) per dose for a 24-week treatment period to maintain study blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Mean Deviation (MD) of Visual FieldTime frame: Day 168 after first study drug administration (Day 1)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
Shantou, Guangdong, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Eye Hospital, Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.